Liquidia Corporation (NASDAQ: LQDA) is a Healthcare company (Medical - Pharmaceuticals) with a market capitalization of $5.1B. The Maz Rating grades it against the other companies in its sector.
Liquidia Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $56.73, Liquidia Corporation trades at 8.1x sales. Over the last twelve months it generated about $631M of revenue and a net loss of $94M. It runs a gross margin of 92.7%, an operating margin of -15.6% and a net margin of -15.1%. It shows return on equity of -116.6%, return on invested capital of -55.7% and a free cash flow yield of 3.9%. On the balance sheet: a debt-to-equity ratio of -6.64 and a current ratio of 1.02. Over the past 52 weeks the share price ranged from $22.31 to $93.61, with a beta of 0.54.
Liquidia Corporation does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 7 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Liquidia Corporation (LQDA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.39% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.27% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.39% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.27% / 33% · Receivables / Mkt Cap (36m) 2.44% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 3.39% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.27% / 33.33% · Receivables / Mkt Cap (24m) 2.44% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 33.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 56.5% / 33.33% · Receivables / Avg Assets (4Q) 18.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 23.7% / 33.33% · (Cash+ST Inv) / Total Assets 58.0% / 33.33% · (Cash+Recv) / Total Assets 75.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Liquidia Corporation (LQDA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Liquidia Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Liquidia Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.